Skip to main content
SpringerLink
Log in

Treatment of Elderly Patients with Multiple Myeloma

  • Chapter
  • First Online:
Multiple Myeloma and Other Plasma Cell Neoplasms

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

In Europe and North America, the majority of patients diagnosed with cancer are over 65 years old. This particularly applies to myeloma that has a median age at diagnosis of 69 years old including 35% of patients diagnosed after 75 and 10% after 85 years of age, Fig. 4.1 (SEER data 2016). This is likely to increase in the years to come especially in Europe where it is foreseen that the percentage of Europeans aged over 65 will increase from 85 million (17% of the population) in 2008 to 151 million (30% of the population) in 2060 (European commission 2009).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alexanian R, Bergsagel DE, Migliore J, Vaughn WK, Howe CD (1968) Melphalan therapy for plasma cell myeloma. Blood 31(1):1–10

    CAS  PubMed  Google Scholar 

  • Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M et al (2013a) Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol Off J Am Soc Clin Oncol 31(22):2806–2809

    Article  Google Scholar 

  • Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M et al (2013b) Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe Francophone du Myélome experience. J Clin Oncol 31(22):2806–2809

    Article  PubMed  PubMed Central  Google Scholar 

  • Azad N, Lemay G (2014) Management of chronic heart failure in the older population. J Geriatr Cardiol JGC 11(4):329–337

    PubMed  Google Scholar 

  • Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124(20):3043–3051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N et al (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish myeloma study group. Eur J Haematol 86(1):16–22

    Article  CAS  PubMed  Google Scholar 

  • Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M et al (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371(10):906–917

    Article  CAS  PubMed  Google Scholar 

  • Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial. Leukemia 26(2):349–355

    Article  CAS  PubMed  Google Scholar 

  • Boyle EM, Fouquet G, Manier S, Gauthier J, Noel MP, Borie C et al (2012) Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Rev Hematol 5(6):617–626. quiz 627

    Article  PubMed  Google Scholar 

  • Chen N, Weiss D, Reyes J, Liu L, Kasserra C, Wang X et al (2014) No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers. Cancer Chemother Pharmacol 73(5):1031–1039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA et al (2001) The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112(3):814–819

    Article  CAS  PubMed  Google Scholar 

  • Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A et al (2015) Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica 100(6):826–833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet Lond Engl 389(10068):519–527

    Article  CAS  Google Scholar 

  • Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A et al (2017) A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102(5):910–921. https://doi.org/10.3324/haematol.2016.162693

    Article  PubMed  PubMed Central  Google Scholar 

  • European commission (2009) Ageing report: economic and budgetary projections for the EU-27 Member States (2008–2060)

    Google Scholar 

  • Facon T (2016) Paper: final analysis of overall survival from the first trial [Internet]. [cited 2017 Apr 3]. Available from: https://ash.confex.com/ash/2016/webprogram/Paper91328.html

  • Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594):1209–1218

    Article  CAS  PubMed  Google Scholar 

  • Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG et al (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93(8):1052–1055

    Article  CAS  PubMed  Google Scholar 

  • Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A et al (2013) Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 27(3):695–701

    Article  CAS  PubMed  Google Scholar 

  • Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M et al (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5):1239–1247

    Article  CAS  PubMed  Google Scholar 

  • Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11):3025–3031

    Article  CAS  PubMed  Google Scholar 

  • Gertz MA, Dingli D (2014) How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 124(6):882–890

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goodnough LT, Schrier SL (2014) Evaluation and management of anemia in the elderly. Am J Hematol 89(1):88–96

    Article  PubMed  PubMed Central  Google Scholar 

  • Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC (2004) Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104(8):2263–2268

    Article  CAS  PubMed  Google Scholar 

  • Harousseau J-L, Attal M (2002) The role of stem cell transplantation in multiple myeloma. Blood Rev 16(4):245–253

    Article  PubMed  Google Scholar 

  • Hirschberg R (2012) Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care 6(3):342–347

    Article  PubMed  Google Scholar 

  • Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol Off J Am Soc Clin Oncol 27(22):3664–3670

    Article  CAS  Google Scholar 

  • Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE et al (2014) Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council myeloma IX study results. Br J Haematol 166(1):109–117

    Article  CAS  PubMed  Google Scholar 

  • Kastritis E, Terpos E, Dimopoulos MA (2013) Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother 14(11):1477–1495

    Article  CAS  PubMed  Google Scholar 

  • Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933–939. quiz 1093

    Article  CAS  PubMed  Google Scholar 

  • Larocca A, Cavallo F, Magarotto V, Palumbo A (2013a) Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age. Blood 122:539

    Google Scholar 

  • Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A et al (2013b) The impact of response on bone-directed therapy in patients with multiple myeloma. Blood 122(17):2974–2977

    Article  CAS  PubMed  Google Scholar 

  • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153

    Article  CAS  PubMed  Google Scholar 

  • Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626

    Article  CAS  PubMed  Google Scholar 

  • Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B et al (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113(15):3435–3442

    Article  CAS  PubMed  Google Scholar 

  • Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M et al (2014) European perspective on multiple myeloma treatment strategies in 2014. Oncologist 19(8):829–844

    Article  PubMed  PubMed Central  Google Scholar 

  • Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO (2014) Chronic kidney disease in the elderly: evaluation and management. Clin Pract Lond Engl 11(5):525–535

    Article  CAS  Google Scholar 

  • Mateos M-V, Oriol A, Martínez-López J, Gutiérrez N, Teruel A-I, de Paz R et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11(10):934–941

    Article  CAS  PubMed  Google Scholar 

  • Mateos M-V, Oriol A, Martínez-López J, Gutiérrez N, Teruel A-I, López de la Guía A et al (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120(13):2581–2588

    Article  CAS  PubMed  Google Scholar 

  • Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M et al (2013) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 24(Suppl 6):vi133–vi137

    Google Scholar 

  • Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ et al (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118(5):1231–1238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P et al (2008) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143(1):46–53

    Article  CAS  PubMed  Google Scholar 

  • O’Donnell EK (2015) Paper: a phase II study of modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) for transplant-ineligible patients with newly diagnosed multiple myeloma [Internet]. [cited 2017 Apr 3]. Available from: https://ash.confex.com/ash/2015/webprogramscheduler/Paper80503.html

  • ONS (2010) Office for National Statistics (ONS) [Internet]. Office for National Statistics [cited 2015 Jan 4]. Available from: http://www.ons.gov.uk/ons/index.html

  • Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825–831

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V et al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112(8):3107–3114

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R et al (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 28(34):5101–5109

    Article  CAS  Google Scholar 

  • Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G et al (2014) International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol 32(6):587–600

    Article  Google Scholar 

  • Patel KV (2008) Epidemiology of anemia in older adults. Semin Hematol 45(4):210–217

    Article  PubMed  PubMed Central  Google Scholar 

  • Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K et al (1992) High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 40(12):1197–1204

    Article  CAS  PubMed  Google Scholar 

  • Price EA, Mehra R, Holmes TH, Schrier SL (2011) Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis 46(2):159–165

    Article  CAS  PubMed  Google Scholar 

  • Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548

    Article  PubMed  Google Scholar 

  • Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al (2013) Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council myeloma IX study. J Clin Oncol Off J Am Soc Clin Oncol 31(20):2540–2547

    Article  Google Scholar 

  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917

    Article  CAS  PubMed  Google Scholar 

  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2013) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 31(4):448–455

    Article  CAS  Google Scholar 

  • SEER data (2016) US Population data 1969–2012-SEER Datasets [Internet]. [cited 2015 Jan 4]. Available from: http://seer.cancer.gov/data/citation.html

  • Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93(1):51–54

    CAS  PubMed  Google Scholar 

  • Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29

    Article  PubMed  Google Scholar 

  • Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol Off J Am Soc Clin Oncol 27(17):2758–2765

    Article  Google Scholar 

  • Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A et al (2013) Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 27(10):1959–1969

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stewart AK, Jacobus SJ, Fonseca R, Weiss M, Callander NS, Chanan-Khan AAA et al (2014) E1A06: a phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM). J Clin Oncol 32(5s):8511. Available from: http://meetinglibrary.asco.org/content/131886-144

    Google Scholar 

  • Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B et al (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116(9):1405–1412

    Article  CAS  PubMed  Google Scholar 

  • Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM et al (2015) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol Off J Am Soc Clin Oncol 33(33):3911–3920

    Article  CAS  Google Scholar 

  • Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H et al (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol Off J Am Soc Clin Oncol 28(19):3160–3166

    Article  CAS  Google Scholar 

  • Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H et al (2014) The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628–636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yamaguchi T (2008) Syncope and sinus bradycardia from combined use of thalidomide and beta-blocker. Pharmacoepidemiol Drug Saf 17(10):1033–1035

    Article  CAS  PubMed  Google Scholar 

  • Zweegman S, Palumbo A, Bringhen S, Sonneveld P (2014) Age and aging in blood disorders: multiple myeloma. Haematologica 99(7):1133–1137

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hopital Huriez, CHRU, Lille, France

    Eileen Mary Boyle & Thierry Facon

  2. Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain

    Maria Victoria Mateos

  3. Takeda Italia, Rome, Italy

    Antonio Palumbo

Authors
  1. Eileen Mary Boyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thierry Facon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Victoria Mateos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Palumbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thierry Facon .

Editor information

Editors and Affiliations

  1. School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    Meletios A. Dimopoulos

  2. Service des Maladies du Sang, CHRU Lille Hôpital Claude Huriez, Lille, France

    Thierry Facon

  3. School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    Evangelos Terpos

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boyle, E.M., Facon, T., Mateos, M.V., Palumbo, A. (2018). Treatment of Elderly Patients with Multiple Myeloma. In: Dimopoulos, M., Facon, T., Terpos, E. (eds) Multiple Myeloma and Other Plasma Cell Neoplasms. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-25586-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-25586-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-25584-2

  • Online ISBN: 978-3-319-25586-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation